HEPATITIS C VIRUS GENOTYPE 1 OR 4 Clinical Trials

5 clinical trials for HEPATITIS C VIRUS GENOTYPE 1 OR 4 across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SOFOSBUVIR/LEDIPASVIR FIXED-DOSE COMBINATION FOR 12 WEEKS IN SUBJECTS WITH CHRONIC GENOTYPE 1 OR 4 HEPATITIS C VIRUS (HCV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 CO-INFECTION — RECRUITING · PHASE3
• A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/LEDIPASVIR FIXED-DOSE COMBINATION + RIBAVIRIN ADMINISTERED IN SUBJECTS INFECTED WITH CHRONIC HCV WHO HAVE ADVANCED LIVER DISEASE OR ARE POST-LIVER TRANSPLANT — RECRUITING · PHASE2
• "A PHASE 3 OPEN LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF PEGYLATED INTERFERON LAMBDA-1A, IN COMBINATION WITH RIBAVIRIN AND DELATASVIR, FOR TREATMENT OF CHRONIC HCV INFECTION WITH TREATMENT NAIVE GENOTYPS 1,2,3 OR 4 IN SUBJECTS CO-INFECTED WITH HIV." — RECRUITING · PHASE3
• AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF OMBITASVIR (OBV), PARITAPREVIR (PTV), RITONAVIR (RTV) WITH OR WITHOUT DASABUVIR (DSV) AND WITH OR WITHOUT RIBAVIRIN (RBV) IN PEDIATRIC SUBJECTS WITH GENOTYPE 1 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION (ZIRCON) — NOT_YET_RECRUITING
• OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE COMBINATION OF OMBITASVIR, PARITAPREVIR/R ± DASABUVIR WITH RIBAVIRIN (RBV) IN ADULT PATIENTS WITH GT1 OR GT4 CHRONIC HCV INFECTION AND RESPONSE TO PRIOR TREATMENT OF EARLY STAGE HEPATOCELLULAR CARCINOMA — COMPLETED

Refine this search